Kinnate Biopharma Inc. financial data

Industry
Pharmaceutical Preparations
Location
11975 El Camino Real, Ste 101, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2023 - Mar 28, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.17K % -34.8%
Debt-to-equity 9.6 % +38.6%
Return On Equity -44.7 % -74.2%
Return On Assets -37.1 % -59.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 47.2M shares +1.41%
Common Stock, Shares, Outstanding 47.1M shares +6.27%
Entity Public Float 76M USD -79.3%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 46.6M shares +5.7%
Weighted Average Number of Shares Outstanding, Diluted 46.6M shares +5.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 90.8M USD +2.97%
General and Administrative Expense 28.2M USD -7.01%
Operating Income (Loss) -121M USD -2.24%
Nonoperating Income (Expense) 8.53M USD +279%
Net Income (Loss) Attributable to Parent -116M USD -29.5%
Earnings Per Share, Basic -2.42 USD/shares +8.33%
Earnings Per Share, Diluted -2.42 USD/shares +8.33%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 57M USD +94.8%
Assets, Current 158M USD -31.5%
Property, Plant and Equipment, Net 2.27M USD -26%
Operating Lease, Right-of-Use Asset 2.49M USD -26.3%
Other Assets, Noncurrent 38K USD -98.1%
Assets 174M USD -37.7%
Accounts Payable, Current 2.03M USD -31.6%
Employee-related Liabilities, Current 2.45M USD -49.3%
Accrued Liabilities, Current 9.07M USD -31.3%
Liabilities, Current 12M USD -30.1%
Operating Lease, Liability, Noncurrent 2.28M USD -28.5%
Liabilities 14.3M USD -29.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -12K USD +99.1%
Retained Earnings (Accumulated Deficit) -372M USD -43.4%
Stockholders' Equity Attributable to Parent 159M USD -28.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 159M USD -28.7%
Liabilities and Equity 174M USD -37.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -27.7M USD -31.5%
Net Cash Provided by (Used in) Financing Activities -9.12M USD -7393%
Net Cash Provided by (Used in) Investing Activities 55.4M USD
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 47.1M shares +6.27%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 18.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 57.4M USD +3.64%
Deferred Tax Assets, Valuation Allowance 81.2M USD +42.7%
Deferred Tax Assets, Gross 82.2M USD +41.3%
Operating Lease, Liability 3.18M USD -24.4%
Payments to Acquire Property, Plant, and Equipment 9K USD -99.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -125M USD -10%
Lessee, Operating Lease, Liability, to be Paid 3.55M USD -26.3%
Property, Plant and Equipment, Gross 3.81M USD 0%
Operating Lease, Liability, Current 892K USD -9.99%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.11M USD -0.09%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.08M USD -12.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 372K USD -40.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 927K USD -16.6%
Deferred Tax Assets, Operating Loss Carryforwards 40.4M USD +18.4%
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 927K USD 0%
Operating Lease, Payments 300K USD
Additional Paid in Capital 531M USD +9.73%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 1.05M USD 0%
Depreciation, Depletion and Amortization 203K USD +250%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 638K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 987K USD -20.9%
Share-based Payment Arrangement, Expense 19.9M USD +1.72%
Operating Leases, Future Minimum Payments, Due in Three Years 1.08M USD 0%
Operating Leases, Future Minimum Payments Due 5.16M USD 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%